KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial.

Daniel M Geynisman, Kateryna Chepynoga, Georgia Yates, Ashley Tate, Murat Kurt, Miraj Y Patel, Siguroli Teitsson, Shreya Mitra, Ronac Mamtani

Clin Genitourin Cancer 23(3) 102335

PMID40204616
PMCID-
DOI10.1016/j.clgc.2025.102335
发表日期2025-04-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Curative potential of adjuvant nivolumab was compared with radical resection only among patients at high risk of recurrence following radical surgery of muscle-invasive urothelial carcinoma (MIUC). METHODS: Using patient-level disease-free survival (DFS) data from CheckMate 274 (n = 709, minimum follow-up, 31.6 months), we applied mixture cure models (MCMs) to the adjuvant nivolumab (NIVO) and placebo (PBO) arms of the intention-to-treat (ITT) population and tumor PD-L1 expression ≥1% subpopulation. DFS was derived for hypothetical "cured" and "uncured" subgroups. DFS for the cured subgroup was estimated using WHO background mortality rates matched to trial demographic characteristics. Uncured DFS was modeled using parametric distributions and characterized with cure fractions by maximum-likelihood methods. Model selection considered clinical plausibility, visual comparisons of model fit, and goodness-of-fit statistics. RESULTS: MCM analysis demonstrated that almost all uncured patients experience recurrence or death within 5 years. Clinically plausible models estimated higher cure fractions in tumor PD-L1 ≥1% subgroup for patients treated with NIVO (PD-L1 ≥1%: 59.1%-61.0% vs ITT: 43.1%-45.1%), and highly similar cure fractions for patients receiving PBO irrespective of their PD-L1 expression (PD-L1 ≥1%: 35.9%-36.4% vs ITT: 36.4%-37.0%). Projected 10-year mean DFS was 4.38 to 4.47 years for NIVO and 3.61 to 3.64 years for PBO in the ITT population, and 5.54 to 5.65 years for NIVO and 3.54 to 3.57 years for PBO in the PD-L1 ≥1% subpopulation. CONCLUSIONS: Adjuvant NIVO for high-risk MIUC was associated with a higher cure fraction than PBO in the ITT and PD-L1 ≥1% populations. Results align with reported survival from the trial and highlight clinical outcomes of interest. CheckMate 274 ClinicalTrials.gov identifier, NCT02632409.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。